Pure Global AI
NCT06318338Recruiting

Virtual Reality to Promote Relaxation Prior to Simulation

Virtual Reality to Promote Mindfulness and Relaxation Prior to Radiation Simulation: A Prospective Pilot Feasibility Study
Abramson Cancer Center at Penn MedicineClinicalTrials.govother
Verified
Study focus
Disease/Condition
Cancer
Drug/Device/Intervention
Virtual Reality Program
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Abramson Cancer Center at Penn Medicine
Location
Philadelphia, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 08, 2024
End date
Mar 01, 2025
Enrollment
25 participants
Primary outcome

Feasibility of a pre-simulation VR platform prior to radiation

Summary

The purpose of this study is to assess the feasibility of a pre-simulation virtual reality
 (VR) platform designed to promote relaxation for cancer patients planned for radiation
 therapy (RT).

ICD-10 classifications
Carcinoid syndromeOther chemotherapyCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Prepuce
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06318338
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06318338 through Pure Global AI's free database. This phase not specified trial is sponsored by Abramson Cancer Center at Penn Medicine and is currently Recruiting. The study focuses on Cancer. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.